Nordson (NDSN) and Ekso Bionics (EKSO) Head-To-Head Review

Nordson (NASDAQ: NDSN) and Ekso Bionics (NASDAQ:EKSO) are both industrial products companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Valuation and Earnings

How to Become a New Pot Stock Millionaire

This table compares Nordson and Ekso Bionics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nordson $2.07 billion 3.68 $295.80 million $5.37 24.47
Ekso Bionics $7.35 million 11.96 -$29.12 million ($0.89) -1.64

Nordson has higher revenue and earnings than Ekso Bionics. Ekso Bionics is trading at a lower price-to-earnings ratio than Nordson, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Nordson and Ekso Bionics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nordson 0 5 6 0 2.55
Ekso Bionics 0 0 1 0 3.00

Nordson presently has a consensus price target of $155.89, indicating a potential upside of 18.65%. Ekso Bionics has a consensus price target of $4.00, indicating a potential upside of 173.97%. Given Ekso Bionics’ stronger consensus rating and higher possible upside, analysts clearly believe Ekso Bionics is more favorable than Nordson.

Volatility & Risk

Nordson has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Ekso Bionics has a beta of -0.6, meaning that its share price is 160% less volatile than the S&P 500.

Insider and Institutional Ownership

66.7% of Nordson shares are owned by institutional investors. Comparatively, 38.7% of Ekso Bionics shares are owned by institutional investors. 2.0% of Nordson shares are owned by insiders. Comparatively, 3.3% of Ekso Bionics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


Nordson pays an annual dividend of $1.20 per share and has a dividend yield of 0.9%. Ekso Bionics does not pay a dividend. Nordson pays out 22.3% of its earnings in the form of a dividend. Nordson has raised its dividend for 4 consecutive years.


This table compares Nordson and Ekso Bionics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nordson 15.85% 30.41% 9.94%
Ekso Bionics -396.04% -246.15% -107.72%


Nordson beats Ekso Bionics on 12 of the 17 factors compared between the two stocks.

Nordson Company Profile

Nordson Corporation engineers, manufactures and markets differentiated products and systems used to dispense, apply and control adhesives, coatings, polymers, sealants, biomaterials, and other fluids, to test and inspect for quality, and to treat and cure surfaces. The Company’s segments include Adhesive Dispensing Systems, Advanced Technology Systems and Industrial Coating Systems. The Adhesive Dispensing Systems segment delivers its precision dispensing and processing technology to various markets. The Advanced Technology Systems segment integrates its product technologies found in progressive stages of a customer’s production process, such as surface treatment, precisely controlled automated, and post-dispense bond testing, optical inspection and X-ray inspection. The Industrial Coating Systems segment provides equipment used primarily for applying coatings, paint, finishes, sealants and other materials, and for curing and drying of dispensed material.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness. The company's Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The company has a license agreement with Lockheed Martin Corporation to develop products for military applications, as well as with OttoBock Healthcare Products Gmbh. It also has a collaboration with Genesis Rehab Services to study opportunities for incorporating skilled nursing facilities. The company was founded in 2005 and is headquartered in Richmond, California. Ekso Bionics Holdings, Inc. operates as a subsidiary of Magee Rehabilitation Hospital.

Receive News & Ratings for Nordson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nordson and related companies with's FREE daily email newsletter.

Leave a Reply